Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 5/20 | 0.58 |
| ▸ | AURKA | O14965 | 4/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | GPR39 | O43194 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068539 | 0.91 | PDE5A (0.71) | PDE5AAURKAPDE3BPDE3APDE2A | |
| SCHEMBL20559835 | 0.90 | PDE5A (0.59) | PDE5AAURKAPDE3BPDE3APDE2A | |
| SCHEMBL20956947 | 0.88 | PDE5A (0.52) | PDE5AAURKANPC1HRH4RET | |
| SCHEMBL289868 | 0.88 | PDE5A (0.60) | PDE5AAURKAPDE3BPDE3APDE2A | |
| SCHEMBL290595 | 0.87 | PDE5A (0.59) | PDE5AAURKAPDE3BPDE3APDE2A | |
| SCHEMBL2680432 | 0.83 | PDE5A (0.60) | PDE5AAURKARET | |
| SCHEMBL26647584 | 0.83 | PDE5A (0.55) | PDE5AAURKAPDE3BPDE3APDE2A | |
| SCHEMBL291221 | 0.83 | PDE5A (0.60) | PDE5AAURKAPDE3BPDE3APDE2A | |
| SCHEMBL5522573 | 0.82 | PDE5A (0.74) | PDE5AAURKAPDE3BPDE3APDE2A | |
| SCHEMBL26647636 | 0.82 | PDE5A (0.83) | PDE5AAURKAPDE3BPDE3APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087614-B2 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-08 | — | — | US | claimed |
| EP-4275752-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION | 2023-04-13 | — | — | US | disclosed |
| CN-115192711-A | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2022-10-18 | — | — | CN | disclosed |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190134055-A1 | Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2019-05-09 | — | — | US | disclosed |
| EP-2846805-B1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORP (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180289632-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2018-10-11 | — | — | US | disclosed |
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2016-01-21 | — | — | US | disclosed |
| US-9220715-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-9119822-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2846805-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | OMEROS CORPORATION (US) | 2014-06-26 | — | — | US | disclosed |
| US-8637528-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2013176877-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2013-10-10 | — | — | US | disclosed |
| EP-2427193-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | Omeros Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129036-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289632-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE5A 8/4885AURKA 2884/4885PDE3B 9/4885 |
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE5A 8/4885AURKA 2884/4885PDE3B 9/4885 |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | PDE7B, PDE4C, PDE4A | PDE5A 8/4885AURKA 2884/4885PDE3B 9/4885 |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | PDE7B, PDE4C, PDE4A | PDE5A 8/4885AURKA 2884/4885PDE3B 9/4885 |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | PDE5A 9/4885AURKA 4000/4885PDE3B 15/4885 |
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | PARK7, PDE7B, PDE7A | PDE5A 9/4885AURKA 4000/4885PDE3B 15/4885 |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE5A 8/4885AURKA 2884/4885PDE3B 9/4885 |
| US-20190134055-A1 | Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE5A 8/4885AURKA 2884/4885PDE3B 9/4885 |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | PDE5A 9/4885AURKA 4000/4885PDE3B 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.